Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Chitinase-3-like protein 1 (CHI3L1) is a secreted glycoprotein involved in macrophage polarization, apoptosis, and inflammation, and carcinogenesis. The expression of CHI3L1 is significantly increased in various inflammatory and immunological diseases, such as rheumatoid arthritis, Alzheimer's disease, and atopic dermatitis. Several studies suggest that CHI3L1 may be a viable therapeutic target for these diseases, given its ability to release various pro-inflammatory cytokines, including interleukin (IL)-1β, IL-4, IL-6, IL-13, tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ). Therefore, CHI3L1 likely plays a role in the development of a broad spectrum of inflammatory diseases. However, the precise pathophysiological and pharmacological mechanisms by which CHI3L1 contributes to these diseases remain to be fully elucidated. This review synthesizes recent findings on the functional roles of CHI3L1 across diverse inflammatory conditions, highlighting its involvement in critical signaling pathways. Moreover, preclinical research underscores the therapeutic potential of CHI3L1 inhibition. Thus, targeted CHI3L1 interventions represent a compelling therapeutic strategy warranting further clinical exploration and validation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408202PMC
http://dx.doi.org/10.4062/biomolther.2025.050DOI Listing

Publication Analysis

Top Keywords

chitinase-3-like protein
8
therapeutic target
8
inflammatory diseases
8
chi3l1
8
diseases
5
therapeutic
4
protein therapeutic
4
inflammatory
4
target inflammatory
4
diseases chitinase-3-like
4

Similar Publications

Background: CKD is strongly associated with cardiovascular disease (CVD), yet the etiology responsible for this link remains elusive. Novel blood and urine biomarkers reflecting kidney tubule dysfunction and injury may provide novel insights to mechanisms linking the kidney to CVD.

Methods: In 470 participants of the Multi-Ethnic Study of Atherosclerosis (MESA) without type 2 diabetes, CVD or CKD, we measured six plasma (kidney injury molecule-1 [KIM-1], monocyte chemoattractant protein-1 [MCP-1], soluble urokinase plasminogen activator receptor [suPAR], tumor necrosis factor receptor [TNFR] 1 and 2, and anti-chitinase-3-like protein 1 [YKL-40]) and six urinary (alpha 1 microglobulin [A-1M], epidermal growth factor [EGF], KIM-1, MCP-1, YKL-40 and uromodulin [UMOD]) kidney tubule health biomarkers.

View Article and Find Full Text PDF

Delineating blood DNA methylation biomarkers for Alzheimer's disease.

Alzheimers Dement

September 2025

Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK.

Epigenetic mechanisms act as mediators of genetic and environmental influences. In Alzheimer's disease, blood-based DNA methylation signatures are increasingly being explored as minimally invasive peripheral biomarkers. We previously reported associations between blood DNA methylation in the CHI3L1 gene (encoding YKL-40) and cerebrospinal fluid (CSF) levels of YKL-40, a marker of neuroinflammation.

View Article and Find Full Text PDF

Background: Plasma biomarkers of neurodegeneration, astrogliosis, and neuroinflammation have been studied as potential biomarkers in neurodegenerative diseases. This study investigated whether these markers may predict phenoconversion to Parkinson's disease or dementia with Lewy bodies (DLB) in idiopathic/isolated REM sleep behavior disorder (iRBD).

Methods: In this longitudinal, single-center, iRBD cohort study (enrolled 2004-2022), plasma glial fibrillary acidic protein (GFAP), interleukin-6 (IL-6), neurofilament light chain (NfL), snare-associated protein 25 (SNAP25), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), and chitinase 3-like protein (YKL-40) were measured using NeuroToolKit (Roche Diagnostics International Ltd).

View Article and Find Full Text PDF

Background: Platform therapies, such as dimethylfumarate, teriflunomide, and interferons beta, are insufficient to control relapsing-remitting multiple sclerosis in many patients. Having biomarkers available to stratify patients as good or poor responders before starting treatment would represent a considerable advance.

Methods: We tested serum and cerebrospinal fluid (CSF) levels of chitinase 3-like 1 (c and s-CHI3L1), soluble trigger receptor expressed on myeloid cells (sTREM2) and neuronal pentraxin 2 (NPTX2), and CSF levels of neurofilament light chains and of interleukin-6 (c-IL6) collected before treatment start in 70 patients in Eastern France.

View Article and Find Full Text PDF

Background: Neuroinflammation and hypertension are involved in Alzheimer's disease (AD). However, their independent and additive impacts on astrocytes and AD-related pathologies have not been fully explored. Hence, this study investigated whether the associations between astrocyte reactivity, measured by cerebrospinal fluid (CSF), Chitinase 3-like protein 1 (CHI3L1/YKL-40), and AD-related pathologies were mediated by neuroinflammation and whether these associations were modified by hypertension.

View Article and Find Full Text PDF